Ad for eyelash drug Latisse goes too far
The first time I saw this commercial for the eyelash-growing drug Latisse (bimatoprost) back in June, I almost wasn’t sure it was real. Sure, we’d blogged on Latisse several times since it received approval from the Food and Drug Administration in late 2008, mainly urging consumers to think hard before using it, given the cost and unsavory risks. But I still couldn’t quite believe the level of glam-infused over-the-topness the commercial imparted, making a powerful prescription drug that can cost more than $100 a month sound like just a really, really cool new makeup item (and featuring superstar Brooke Shields, no less). If I didn’t know better (and it wasn’t a Tuesday), I would have thought it was a Saturday Night Live skit, like this hilarious take on extended-cycle birth-control pills.
The Latisse commercial might portray it as the new big thing, but it’s not really new at all; it originated as Lumigan, a glaucoma medication approved in 2001 that, in a stroke of pure luck for its manufacturer, turned out to have the unusual side effect of lengthening, thickening, and darkening users’ eyelashes. Hence, a rebranding as the first FDA approved treatment for sparse or inadequate eyelashes, clinically known as hypotrichosis. A representative for Brooke Shields declined to say how long Brooke has suffered from the disease of eyelash inadequacy. But she did confirm that Brooke started using Latisse in February 2009, “after consulting with a doctor who determined she was an appropriate candidate for treatment with LATISSE,” and that she is still using it. If you’re good at math, you’ll know that adds up to around $800 worth of eyelash improvement and counting.
The fact that the Latisse commercial looks like an ad for makeup rather than a drug is only the beginning of what completely freaks me out about it. Somehow this single commercial and its print companions running in magazines like Allure manages to embody everything that’s wrong about direct-to-consumer drug advertising. Specifically:
Continue reading "Ad for eyelash drug Latisse goes too far" »











